Clinical-stage biotech company Lytix Biopharma AS (Euronext Growth Oslo:LYTIX) on Tuesday announced encouraging interim data from the ongoing Phase 2 NeoLIPA study evaluating ruxotemitide, in combination with pembrolizumab, as a neoadjuvant treatment for resectable melanoma at Oslo University Hospital – The Norwegian Radium Hospital.

Among the first nine evaluable patients out of 13 enrolled, the combination therapy demonstrated an 88% overall pathological response rate. Major pathological responses were observed in 55% of patients, while 44% achieved a pathologic complete response with no viable tumour cells detected. No relapses have been reported to date, and the treatment has shown a favourable safety profile.

The results highlight ruxotemitide's intratumoural, immunogenic mechanism of action, designed to modify the tumour microenvironment and stimulate a systemic anti-tumour immune response before surgery.

Based on these findings, Lytix Biopharma plans to accelerate the development of ruxotemitide in the neoadjuvant melanoma setting, targeting an efficient path toward regulatory approval.